Acute myocardial infarction with ST segment elevation MedDRA version: 6.1 Level: PT Classification code 10000891
Conditions
Interventions
Trade Name: KRENOSIN*EV 6F 2ML 6MG/2ML
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Adenosine
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 6-
Sponsors
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Symptoms onset =65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. age less than 18 years 2. previous STEMI 3. patients presenting in cardiogenic shock 4. pregnancy 5. patients with renal failure 6. contraindications to contrast agents, which cannot be managed medically or study mediactions, including aspirin, clopidogrel and ticlopidine, and heparin Electrocardiogram 7. left bundle branch block, paced rhythm, frequent ventricular ectopy, pre-excitation or other conditions or artifacts interfering with interpretation of ST segment resolution Angiography 8. culprit lesion located in a by-pass graft 9. stent thrombosis 10. culprit lesion non identified 11. left main disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Aim of this randomized study is to assess the effect of nitroprusside or adenosine in adjunct to current best therapy (thrombus aspiration and IIb-IIIa antagonists) for ST elevation MI;Secondary Objective: 1) rate of angiographic no-reflow; 2) changes of LV volumes at follow-up; 3) rate of no-reflow on IC ECG; 4) rate of no-reflow at echocontrastography; 5) rate of MACEs;Primary end point(s): Primary end-point of the study will be rate of ST resolution on surface ECG. | — |
Countries
Italy
Outcome results
None listed